CTTQ-Akeso
CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. (CTTQ-Akeso), with registered capital of RMB 690 million, is an innovative biomedical company jointly established by Akeso, Inc. (9926.HK) and Chia Tai Tianqing Pharmaceutical Group Co., Ltd... CTTQ-Akeso focuses on the R&D of innovative biologics, industrialization of research results, technology transfer and commission processing, and is committed to the R&D and commercialization of the anti PD-1 monoclonal antibody drug Penpulimab monoclonal antibody injection (Anikora®) for tumor immunotherapy.
In April 2023，CTTQ-Akesoentered into a partnership agreement with Specialised Therapeutics （ST）to commercialise Anikora® in Australia, New Zealand, Papua New Guinea and 11 countries in Southeast Asia including Singapore and Malaysia.The total consideration for the cooperation amounts to approximately US$73 million, and CTTQ-Akeso shall be entitled to a double-digit commission on the net sales of the drug in authorized regions.Through differentiated advantages of Anikora® ，the partnership will robust its market presence in Southeast Asia and has become a powerful extension and supplement of the company's commercialization system in overseas markets.
Fenglin Building, No.420 Fenglin Road, Xuhui District, Shanghai
400-008-5183 (working days: 9:00–17:00)
Note: If your report involves an adverse event of CTTQ-Akeso’s products, the relevant patient information and data will be disclosed to CTTQ-Akeso’s pharmacovigilance department in accordance with the applicable laws and regulations, and the relevant personnel may follow up with you on the adverse event. The information will be input into CTTQ-Akeso’s drug safety database and may be legally required to reported to relevant regulatory departments.
